News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Graham Watt Joins Caldera Health as Managing Director

9/11/2013 8:33:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Auckland, 11 September 2013 – Prostate cancer diagnostics company, Caldera Health, has appointed Graham Watt as managing director.

Caldera’s Chairman, Dr Alastair MacCormick, says that Graham’s knowledge of the global diagnostics market, his experience in the industry and his extensive international networks will be invaluable for the company.

“Graham has an understanding of the global medical diagnostics industry and an unmatched network of connections,” said Dr MacCormick. “He brings many years of experience in diagnostic business development and the structuring of high growth organisations. We’re delighted to have lured Graham out of retirement to join the board and head the business.” Mr Watt has 40 years’ experience in medical diagnostics, mainly in senior international management roles with global leader, Roche Diagnostics.

“Caldera Health is working to improve the diagnosis of prostate cancer using cutting edge genetic technology,” said Mr Watt. “There is a tremendous opportunity to add new tools of genetic analysis to prostate cancer diagnosis and achieve significantly better outcomes for the large numbers of men worldwide who are affected by this disease. Each year in New Zealand approaching 1,000 men die of prostate cancer.”

Founder Dr Jim Watson, in his new role as director of science, now heads development on the company’s prostate diagnostic test.

“I’m delighted to have someone as widely known and well respected throughout the diagnostics industry as Graham leading Caldera Health,” said Dr Watson.

About Caldera Health

Caldera Health is a New Zealand biotech developing a gene-based diagnostic test for prostate cancer. There are no comparable diagnostic tests for prostate cancer in the market today.

The business goal is to replace the standard PSA test and the digital rectal examination as the global test for prostate cancer.


Dr Alastair MacCormick, Chairman: +64 21 640 010,

Allan Botica (Botica Butler Raudon): +64 21 400 500,

Allan Botica

Botica Butler Raudon Partners

M: +64 21 400 500 | T: +64 9 303 3862 | E: | W: | F: +64 9 303 3610 | Skype: allanbotica Google+ | Facebook: | Twitter:!/boticapr

Mail: PO Box 3932, Shortland Street, Auckland 1140

Office: Ground Floor, Textile Centre, Kenwyn Street, Parnell, Auckland 1052

New Zealand. (Google Maps:

Help employers find you! Check out all the jobs and post your resume.

Read at

comments powered by Disqus